<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02446574</url>
  </required_header>
  <id_info>
    <org_study_id>02-27/230</org_study_id>
    <nct_id>NCT02446574</nct_id>
  </id_info>
  <brief_title>Postoperative Chemoradiation in Patients With Node-positive Esophageal Squamous Cell Carcinoma</brief_title>
  <official_title>Phase I /II Study of Postoperative Chemoradiation in Patients With Node-positive Esophageal Squamous Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a unicentered phase I/II study to explore the dose of paclitaxel and cisplatin with
      radiation therapy, and to document the adverse events for further clinical trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Although preoperative chemoradiation therapy followed by surgery is the most common approach
      for patients with resectable esophageal cancer, the considerable number of esophageal cancer
      patients received operation as the first treatment modality. Accordingly, postoperative
      treatments have been playing an important role because of the poor survival rates of the
      patients with pathologically positive lymph nodes who have been treated with resection alone.
      The investigators have proved the value of prophylactic radiation therapy after radical
      esophagectomy for esophageal carcinoma with positive lymph node metastases under the
      conventional 2-dimensional radiotherapy methods in subset analysis of prospective randomized
      clinical trial. For patients with positive lymph nodes, 5 year survival after surgery alone
      was 28.4%, median overall survival was 24 months, recurrence occurred 34.6% in mediastinal
      lymph nodes，13.3% in supraclavicular lymph nodes，10% in abdominal lymph nodes. Distant
      metastases occurred in 21% patients. Adjuvant radiotherapy significantly reduced the
      recurrence in mediastinal lymph nodes(13.4%), supraclavicular lymph nodes (6.1%). However
      distant metastases rate increased to 30.7%. Chemotherapy may be vital for these patients.
      Chen reported that the 5 year overall survival rates for the chemoradiotherapy group and
      radiotherapy group were 47.4% and 38.6% (P=0.03). Based on the investigators' studies,
      treatment failure occurred in 8% patients because of celiac metastases. Small radiation field
      by omitting celiac axis lymph node basin may ensure 5-6 cycles of concurrent chemotherapy for
      lower toxicity.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose of weekly paclitaxel and cisplatin with concurrent radiation(Phase I endpoint)</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicities according to the Common Terminology Criteria for Adverse Events version 3.0.</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival survival of weekly paclitaxel and cisplatin with concurrent radiation(Phase II endpoint)</measure>
    <time_frame>60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival of weekly paclitaxel and cisplatin with concurrent radiation(Phase II endpoint)</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Esophageal Neoplasms</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During the Phase I it will administered weekly paclitaxel(dose escalation) and cisplatin with concurrent radiation therapy
During the Phase II it will administered weekly paclitaxel(dose according to phase I) and cisplatin with concurrent radiation therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>starting dose 20mg/m2 qw</description>
    <arm_group_label>Arm A</arm_group_label>
    <other_name>taxel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>dose 25mg/m2 qw</description>
    <arm_group_label>Arm A</arm_group_label>
    <other_name>platimum</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation</intervention_name>
    <description>60Gy/2Gy/30f</description>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. KPS≥70

          2. Diagnosis of pathologically positive lymph node thoracic esophageal cancer

          3. Complete resection

          4. Adequate organ function:

        Hematopoietic Absolute granulocyte count at least 1,500/mm^3 Platelet count at least
        150,000/mm^3 Hemoglobin at least 10 g/dL Hepatic Not specified Renal Creatinine no greater
        than 1.5 mg/dL AND/OR Creatinine clearance at least 65 mL/min Calcium no greater than 11
        mg/dL Cardiovascular No uncontrolled heart disease No uncontrolled hypertension

        Exclusion Criteria:

          1. Uncontrolled diabetes

          2. Interval between surgery and adjuvant therapy more than 3 months

          3. Sign of recurrence on CT scan or ultrasound or PET-CT No palpable supraclavicular
             lymph nodes or involvement after cytology needle aspiration No lymph nodes greater
             than 1 cm on CT scan

          4. With Weight loss greater than 10% from baseline

          5. With other prior or concurrent malignancy except basal cell skin cancer or carcinoma
             in situ of the cervix

          6. Be pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>68 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zefen Xiao, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Radiation Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Science</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cancer Institute and Hospital, Chinese Academy of Medical Science</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Rizk N, Venkatraman E, Park B, Flores R, Bains MS, Rusch V; American Joint Committee on Cancer staging system. The prognostic importance of the number of involved lymph nodes in esophageal cancer: implications for revisions of the American Joint Committee on Cancer staging system. J Thorac Cardiovasc Surg. 2006 Dec;132(6):1374-81.</citation>
    <PMID>17140960</PMID>
  </results_reference>
  <results_reference>
    <citation>Korst RJ, Rusch VW, Venkatraman E, Bains MS, Burt ME, Downey RJ, Ginsberg RJ. Proposed revision of the staging classification for esophageal cancer. J Thorac Cardiovasc Surg. 1998 Mar;115(3):660-69; discussion 669-70.</citation>
    <PMID>9535455</PMID>
  </results_reference>
  <results_reference>
    <citation>Rice TW, Blackstone EH, Rybicki LA, Adelstein DJ, Murthy SC, DeCamp MM, Goldblum JR. Refining esophageal cancer staging. J Thorac Cardiovasc Surg. 2003 May;125(5):1103-13.</citation>
    <PMID>12771884</PMID>
  </results_reference>
  <results_reference>
    <citation>Hagen JA, DeMeester SR, Peters JH, Chandrasoma P, DeMeester TR. Curative resection for esophageal adenocarcinoma: analysis of 100 en bloc esophagectomies. Ann Surg. 2001 Oct;234(4):520-30; discussion 530-1.</citation>
    <PMID>11573045</PMID>
  </results_reference>
  <results_reference>
    <citation>Igaki H, Kato H, Tachimori Y, Nakanishi Y. Prognostic evaluation of patients with clinical T1 and T2 squamous cell carcinomas of the thoracic esophagus after 3-field lymph node dissection. Surgery. 2003 Apr;133(4):368-74.</citation>
    <PMID>12717353</PMID>
  </results_reference>
  <results_reference>
    <citation>van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, Richel DJ, Nieuwenhuijzen GA, Hospers GA, Bonenkamp JJ, Cuesta MA, Blaisse RJ, Busch OR, ten Kate FJ, Creemers GJ, Punt CJ, Plukker JT, Verheul HM, Spillenaar Bilgen EJ, van Dekken H, van der Sangen MJ, Rozema T, Biermann K, Beukema JC, Piet AH, van Rij CM, Reinders JG, Tilanus HW, van der Gaast A; CROSS Group. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012 May 31;366(22):2074-84. doi: 10.1056/NEJMoa1112088.</citation>
    <PMID>22646630</PMID>
  </results_reference>
  <results_reference>
    <citation>Rice TW, Adelstein DJ, Chidel MA, Rybicki LA, DeCamp MM, Murthy SC, Blackstone EH. Benefit of postoperative adjuvant chemoradiotherapy in locoregionally advanced esophageal carcinoma. J Thorac Cardiovasc Surg. 2003 Nov;126(5):1590-6.</citation>
    <PMID>14666038</PMID>
  </results_reference>
  <results_reference>
    <citation>Liu HC, Hung SK, Huang CJ, Chen CC, Chen MJ, Chang CC, Tai CJ, Tzen CY, Lu LH, Chen YJ. Esophagectomy for locally advanced esophageal cancer, followed by chemoradiotherapy and adjuvant chemotherapy. World J Gastroenterol. 2005 Sep 14;11(34):5367-72.</citation>
    <PMID>16149148</PMID>
  </results_reference>
  <results_reference>
    <citation>Hsu PK, Huang CS, Wang BY, Wu YC, Hsu WH. Survival benefits of postoperative chemoradiation for lymph node-positive esophageal squamous cell carcinoma. Ann Thorac Surg. 2014 May;97(5):1734-41. doi: 10.1016/j.athoracsur.2013.12.041. Epub 2014 Mar 6.</citation>
    <PMID>24612702</PMID>
  </results_reference>
  <results_reference>
    <citation>Chen J, Pan J, Liu J, Li J, Zhu K, Zheng X, Chen M, Chen M, Liao Z. Postoperative radiation therapy with or without concurrent chemotherapy for node-positive thoracic esophageal squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2013 Jul 15;86(4):671-7. doi: 10.1016/j.ijrobp.2013.03.026.</citation>
    <PMID>23773390</PMID>
  </results_reference>
  <results_reference>
    <citation>Xiao ZF, Yang ZY, Liang J, Miao YJ, Wang M, Yin WB, Gu XZ, Zhang DC, Zhang RG, Wang LJ. Value of radiotherapy after radical surgery for esophageal carcinoma: a report of 495 patients. Ann Thorac Surg. 2003 Feb;75(2):331-6.</citation>
    <PMID>12607634</PMID>
  </results_reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 26, 2015</study_first_submitted>
  <study_first_submitted_qc>May 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 18, 2015</study_first_posted>
  <last_update_submitted>October 20, 2017</last_update_submitted>
  <last_update_submitted_qc>October 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Zefen Xiao</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>chemoradiation</keyword>
  <keyword>dose escalation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

